Welcome to our dedicated page for Arbutus Biopharm SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arbutus Biopharma’s disclosures are packed with clinical-trial data, cash-runway tables, and patent-litigation details that can stretch beyond 200 pages. Finding the HBV pipeline timeline in a 10-K or spotting a fresh partnership update in an 8-K shouldn’t take all afternoon. That’s why this page brings every SEC document—plus instant context—into one clear view.
Our platform reads each incoming filing, from an Arbutus Biopharma annual report 10-K simplified to an Arbutus Biopharma 8-K material events explained, and produces AI-powered briefs that highlight what matters: Phase 1b results, RNAi manufacturing costs, or new LNP licensing revenue. Need executive-deal insights? Track Arbutus Biopharma Form 4 insider transactions in real-time and receive alerts when directors buy or sell. Want fast financials? Every Arbutus Biopharma quarterly earnings report 10-Q filing comes with side-by-side trend analysis, so you can compare R&D burn rates quarter over quarter.
Common questions are answered at a glance: “How do I read Arbutus Biopharma’s proxy statement executive compensation?” or “Where is the latest Arbutus Biopharma insider trading Form 4 transactions list?”—they’re all here, automatically tagged and searchable. Whether you’re monitoring cash reserves before a pivotal trial or understanding Arbutus Biopharma SEC documents with AI to gauge litigation risk, Stock Titan delivers the clarity biotech investors demand. No more hunting through EDGAR; every filing type, from S-3 shelf registrations to detailed earnings report filing analysis, is updated the moment it hits the regulator’s site.
Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025. The stake is held in two funds — 7,472,841 shares in the Two Seas Global (Master) Fund and 2,970,476 shares in the Two Seas LNP Opportunities (Master) Fund — and the reporting persons state they have sole voting and sole dispositive power over all reported shares. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The disclosure references a total share count of 191,641,511 common shares used to calculate the percentage.
ABUS Q2-25 showed a sharp swing to profitability as one-time license revenue and deep cost cuts outweighed lower investment income. Total revenue rose to $10.7 m from $1.7 m a year earlier, driven mainly by recognition of $9.6 m in deferred revenue after the June termination of the Qilu partnership, which also returns worldwide rights to imdusiran. Non-cash royalty revenue from Alnylam’s ONPATTRO contributed $0.5 m.
Operating expenses fell 60% YoY to $9.3 m following a 57% workforce reduction, facility exit and R&D scale-back; Q1 restructuring charges totaled $12.4 m. As a result, operating income reached $1.5 m versus a $21.6 m loss last year, and net income reached $2.5 m ($0.01/share) versus a $19.8 m loss. For the six months, the company still posted a $22.0 m loss, but cash burn declined (operating cash outflow $29.1 m vs $33.8 m).
Cash, cash equivalents and short-term securities were $98.1 m at 30-Jun-25 (down from $122.6 m at year-end) with no debt; management expects runway of ≥12 months. Total assets fell to $103.3 m, liabilities to $20.3 m and equity to $83.0 m. Contingent consideration stands at $10.8 m and the liability from royalty-sale to OMERS declined to $3.9 m.
Key catalysts include Phase 2 data from imdusiran combinations, ongoing Phase 1a/1b dosing of oral PD-L1 inhibitor AB-101, and patent litigation milestones against Moderna and Pfizer/BioNTech (trial in Mar-26). Cost-control measures and regained global rights position Arbutus for partnering, but termination of Qilu removes future milestone streams.
Arbutus Biopharma (NASDAQ:ABUS) announced the termination of its technology transfer and license agreement with Qilu Pharmaceutical Co., Ltd. The agreement, originally established in December 2021, granted Qilu exclusive rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan.
The mutual termination, effective June 20, 2025, involves no financial payments and results in all rights for imdusiran in Greater China and Taiwan reverting to Arbutus. This decision aligns with Qilu's pipeline reprioritization and Arbutus's strategic focus on efficient pipeline advancement.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
